Leap Therapeutics Files 8-K Report
Ticker: CYPH · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, pharmaceuticals
TL;DR
Leap Therapeutics filed an 8-K on 9/30/24 for corporate updates.
AI Summary
On September 30, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is based in Cambridge, MA, and operates in the pharmaceutical preparations sector. This filing serves as a current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing provides an update on Leap Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Numbers
- 27-4412575 — IRS Employer Identification No. (Company's tax identification number)
- 02141 — ZIP Code (Principal executive offices ZIP code)
Key Players & Entities
- Leap Therapeutics, Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Principal executive offices
- 001-37990 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as a current report under Section 13 or 15(D) of the Securities Exchange Act of 1934.
When was the earliest event reported in this filing?
The earliest event reported was on September 30, 2024.
Where are Leap Therapeutics, Inc.'s principal executive offices located?
Leap Therapeutics, Inc.'s principal executive offices are located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.
What is the Commission File Number for Leap Therapeutics, Inc.?
The Commission File Number for Leap Therapeutics, Inc. is 001-37990.
What is the Standard Industrial Classification code for Leap Therapeutics, Inc.?
The Standard Industrial Classification code for Leap Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-09-30 07:30:29
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate
Filing Documents
- tm2425162d1_8k.htm (8-K) — 26KB
- tm2425162d1_ex99-1.htm (EX-99.1) — 12KB
- tm2425162d1_ex99-1img001.gif (GRAPHIC) — 2KB
- 0001104659-24-103942.txt ( ) — 214KB
- lptx-20240930.xsd (EX-101.SCH) — 3KB
- lptx-20240930_lab.xml (EX-101.LAB) — 33KB
- lptx-20240930_pre.xml (EX-101.PRE) — 22KB
- tm2425162d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events On September 30, 2024, Leap Therapeutics, Inc. (the "Company") issued a press release entitled "Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients." The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however that information on or connected to our website referenced in the Company's press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated September 30, 2024. 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.) - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: September 30, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President - 3 -